| 0.6548 -0.016 (-2.36%) | 01-26 14:45 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.87 | 1-year : | 1.01 |
| Resists | First : | 0.74 | Second : | 0.87 |
| Pivot price | 0.66  |
|||
| Supports | First : | 0.62 | Second : | 0.55 |
| MAs | MA(5) : | 0.68 |
MA(20) : | 0.65 |
| MA(100) : | 0.64 |
MA(250) : | 0.99 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 50.3 |
D(3) : | 64.6 |
| RSI | RSI(14): 49.3 |
|||
| 52-week | High : | 2.95 | Low : | 0.5 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ LFWD ] has closed above bottom band by 40.5%. Bollinger Bands are 34.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.71 - 0.72 | 0.72 - 0.72 |
| Low: | 0.66 - 0.66 | 0.66 - 0.67 |
| Close: | 0.66 - 0.67 | 0.67 - 0.68 |
Lifeward Ltd. is a medical device company, which engages in the design, development and marketing of wearable robotic exoskeletons. The firm's exoskeletons provide hip and knee motion to enable individuals with spinal cord injury (SCI) to stand upright, walk, turn, and climb and descend stairs. Its products include ReWalk Exo-Suit and ReWalk Personal 6.0. The company was founded by Amit Goffer on June 20, 2001 and is headquartered in Marlborough, MA.
Tue, 13 Jan 2026
Lifeward Enters Transformative Strategic Investment and - GlobeNewswire
Tue, 13 Jan 2026
Oramed and Lifeward Announce Strategic Transaction - PR Newswire
Tue, 13 Jan 2026
Oral insulin bid: Lifeward-Oramed eye $634B injectable market shift - Stock Titan
Tue, 13 Jan 2026
Lifeward Signs Multiple Material Agreements - TradingView
Fri, 19 Dec 2025
Lifeward appoints Bob Marshall as new board chairman - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 18 (M) |
| Shares Float | 17 (M) |
| Held by Insiders | 1.7 (%) |
| Held by Institutions | 4.6 (%) |
| Shares Short | 1,590 (K) |
| Shares Short P.Month | 1,370 (K) |
| EPS | -2.92 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.75 |
| Profit Margin | -121.9 % |
| Operating Margin | -50.7 % |
| Return on Assets (ttm) | -32.3 % |
| Return on Equity (ttm) | -128 % |
| Qtrly Rev. Growth | 1.1 % |
| Gross Profit (p.s.) | 0.48 |
| Sales Per Share | 1.33 |
| EBITDA (p.s.) | -0.91 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -17 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -0.23 |
| PEG Ratio | 0 |
| Price to Book value | 0.86 |
| Price to Sales | 0.48 |
| Price to Cash Flow | -0.7 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|